Serum Pepsinogen I, Pepsinogen II, and Gastrin 17 in Relatives of Gastric Cancer Patients: Comparative Study With Type and Severity of Gastritis

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 2, 2008, Pages 174-179

  Haj sheykholeslami, Arghavan ^a   Rakhshani, Naser ^a,d   Amirzargar, Aliakbar ^b   Rafiee, Reza ^c   Shahidi, S Mehdi ^b   Nikbin, Behrouz ^b   Khosravi, Farideh ^b   Massarrat, Sadegh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GASTRIN 17; PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; SCREENING; STOMACH BIOPSY; STOMACH CANCER; SYDNEY CLASSIFICATION;

ADULT; BIOLOGICAL MARKERS; BIOPSY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAMILY; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTRITIS; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; SENSITIVITY AND SPECIFICITY; SERUM; STOMACH NEOPLASMS;

EID: 38649087648     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.11.016     Document Type: Article

References (47)

1. Correa P. Human gastric carcinogenesis, a multistep and multifactorial process. Cancer Res 52 (1992) 6735-6740
2. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001) 784-789
3. Oishi Y., Kiyohara Y., Kubo M., et al. The serum pepsinogen test as a predictor of gastric cancer. Am J Epidemiol 163 (2006) 629-637
4. Kitahara F., Koba Nardone G., et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 22 (2005) 1139-1146
5. Miki K., Morita M., Sasajima M., et al. Usefulness of gastric screening using the serum pepsinogen test method. Am J Gastroenterol 98 (2003) 735-739
6. Oksanen A., Sipponen P., Karttunen R., et al. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 46 (2000) 460-463
7. Vaananen H., Vaukonen M., Helske T., et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicenter study. Eur J Gastroenterol Hepatol 15 (2003) 885-891
8. Nardone G., Rocco A., Staibano S., et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 22 (2005) 1139-1146
9. Morales T.G., Sampliner R.E., Camargo E., et al. Inability of noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with helicobacter eradication. J Clin Gastroenterol 32 (2001) 400-404
10. Pasechnikov V.D., Cuukov S.Z., Kotelvets M., et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis, a comparative study. Scand J Gastroenterol 40 (2005) 297-301
11. Sanduleanu S., Bruine A.D.E., Biemond I., et al. Ratio between serum IL-8 and Pepsinogen A/C, a marker for atrophic body gastritis. Eur J Clin Invest 33 (2003) 147-154
12. Shiotani A., Iishi H., Uedo N., et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 115 (2005) 463-469
13. Knight T., Wyatt J., Wilson A., et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population, development of a biomarker strategy for gastric atrophy in high-risk groups. Br J Cancer 73 (1996) 819-824
14. Borch K., Axelsson C.K., Halgreen H., et al. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 24 (1989) 870-876
15. Graham D.Y., Nurgalieva Z.Z., El-Zimaity H.M.T., et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 4 (2006) 303-314
16. Correa P. Is gastric cancer preventable?. Gut 53 (2004) 1217-1219
17. Stolte M., and Meining A. Helicobacter pylori gastritis of the gastric carcinoma phenotype: is histology capable of identifying high-risk gastritis. J Gastroenterology 35 (2000) 98-101
18. Lehtola J. Family study of gastric carcinoma: with special reference to special types. Scand J Gastroenterol 13 Suppl 50 (1978) 1-40
19. La Vecchia C., Negri E., Franceschi S., et al. Family history and the risk of stomach and colorectal cancer. Cancer 70 (1992) 50-55
20. El-Omar E.M., Oien K., Murray L.S., et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 118 (2000) 22-30
21. Correa P. The epidemiology of gastric cancer. World J Surg 15 (1991) 228-234
22. Islami F., Kamangar F., Aghcheli K., et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer 90 (2004) 1402-1406
23. Kuipers E.J. Relation between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 12 suppl 1 (1998) 25-36
24. Mirsky A., Futterman P., and Kaplan S. Blood plasma pepsinogen. The activity of the plasma from normal subjects, patients with duodenal ulcer and patients with pernicious anemia. J Lab Clin Med 40 (1952) 188-199
25. Chinn A.B. Studies on a blood serum proteolytic enzyme with particular reference to gastric secretory function. Gastroenterology 25 (1953) 14-23
26. Spiro H.M., Ryan A.E., and Jones C.M. The utility of the blood pepsin assay in clinical medicine. N Engl J Med 28 (1955) 402-406
27. Samloff I.M., and Liberman W.M. Cellular localization of group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 65 (1973) 36-42
28. Hirsch-Marie H., Loisillier F., and Tauboul J.P. Immunochemical study and cellular localization of human pepsinogens during ontogenesis and in gastric cancers. Lab Invest 34 (1976) 623-632
29. Zöller M., Matzku M., and Rapp S. Purification of human gastric proteases by immunoadsorbents: pepsinogen I-group. Biochem Biophys Acta 427 (1976) 708-712
30. Matzku M., and Rapp S. Purification of human gastric proteases by immunoabsorbents: pepsinogen II-group. Biochem Biophys Acta 446 (1976) 30-40
31. Samloff I.M., Liberman W.M., and Panitch N.M. Serum group I pepsinogen by radioimmunoassay in control subjects and patients with peptic ulcer. Gastroenterology 69 (1975) 83-90
32. Samloff I.M., Secrist D.M., and Passaro E. A study of the relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology 69 (1975) 1196-1200
33. Samloff I.M., Secrist D.M., and Passaro E. Effect of betazole on serum group I pepsinogen levels: relationship to gastric acid output in unoperated and postoperative patients. Gastroenterology 72 (1977) 845-848
34. Sipponen P., Valle J., Varis K., et al. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa, an analysis of 860 subjects. Scand J Gastroenterol 25 (1990) 513-519
35. Stemmermann G.N., Samloff I.M., Nomura A.M., et al. Serum pepsinogen I and II and stomach cancer. Clin Chim Acta 163 (1987) 191-198
36. You W.C., Blot W.J., Zhang L., et al. Serum pepsinogen in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev 2 (1993) 113-117
37. Westerveld B.D., Pals G., Lamers C.B., et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 59 (1987) 952-958
38. Broutet N., Plebani M., Sakarovitch C., et al. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic gastritis in European dyspeptics. Br J Cancer 88 (2003) 1239-1247
39. Ley C., Mohar A., Guarner J., et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev 10 (2001) 107-112
40. Ricci C., Vakil N., Rugge M., et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 99 (2004) 1910-1915
41. Bodger K., Wyatt J.I., and Heatley R.V. Variation in serum pepsinogen with severity and topography of helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 6 (2001) 216-224
42. Hallissaey M.T., Dunn J.A., and Fielding J.W.L. Evaluation of pepsinogen A and Gastrin-17 as markers of gastric cancer and high risk pathologic conditions. Scand J Gastroenterol 29 (1994) 1129-1134
43. Sipponen P., Ranta P., Helske T., et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 37 (2002) 785-791
44. Sitas F., Smallwood L., Jewell D., et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev 2 (1993) 119-123
45. Massarrat S. Serum pepsin activity as parameter of gastric acid secretion. Hepatogastroenterology 32 (1985) 185-190
46. Watabe H., Mitsushima T., Yamaji Y., et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54 (2005) 764-768
47. Correa P., Fontham E.T.H., Bravo J.C., et al. Chemoprevention of gastric dysplasia, randomized trial of antioxidants supplements and anti helicobacter pylori therapy. J Natl Cancer Inst 92 (2000) 1181-1188